Skip to main content
. 2022 Feb 25;14(5):1195. doi: 10.3390/cancers14051195

Figure 6.

Figure 6

Furin silencing mediates repression of LGR5 and NANOG in KRAS or BRAF mutated tumors. (a–c), PCs activity was analyzed by assessing the ability of the colon cancer cell lines DLD1 with KRAS mutation, HT29 with BRAF mutation and HCA7 with WT KRAS and BRAF with silenced (KO) Furin to digest the fluorogenic peptide pERTKR-MCA in the in vitro enzymatic digestion assay. (d,f), Results shown in the bar graph represent PCs activity after 20 min of incubation. (e),Furin silencing mediates repression of LGR5 and NANOG in KRAS or BRAF mutated tumors. (g–l), Results shown in the bar graph represent NANOG (g–i) and LGR5 (j–l) expression analyzed by real-time PCR in the developed tumors derived from control DLD1, HT29 and HCA7 and the same cells with silenced Furin. Results are representative of three experiments and data are mean ± S.E.M performed in triplicate. * p < 0.05. NS: not significant.